Complete Reversion of Imatinib-Induced Hepatotoxicity in Chronic Myeloid Leukemia Patients by Low-Intermediate Dose Corticosteroid.
Dario Ferrero(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Mario Boccadoro(University of Turin), Valentina Giai(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Paola Perfetti(Azienda Ospedaliera San Gerardo), Monica Fumagalli(University of Milan), Giovanna Rege‐Cambrin, Carmen Fava, Chiara Maria Dellacasa(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Mariella Genuardi, Enrico Maria Pogliani(Azienda Ospedaliera San Gerardo), Giovanna Mattioli(Ospedale San Luigi Gonzaga)
Cited by 8
Related Papers
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders
|Leukemia|2008|808
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
|Leukemia|2011|721
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
|New England Journal of Medicine|2023|538